| 000 | 01394 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250512022745.0 | ||
| 264 | 0 | _c19850711 | |
| 008 | 198507s 0 0 eng d | ||
| 022 | _a0012-6667 | ||
| 024 | 7 |
_a10.2165/00003495-198529040-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aClark, D W | |
| 245 | 0 | 0 |
_aGenetically determined variability in acetylation and oxidation. Therapeutic implications. _h[electronic resource] |
| 260 |
_bDrugs _cApr 1985 |
||
| 300 |
_a342-75 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAcetylation |
| 650 | 0 | 4 |
_aAnticonvulsants _xmetabolism |
| 650 | 0 | 4 |
_aAntidepressive Agents, Tricyclic _xmetabolism |
| 650 | 0 | 4 |
_aDebrisoquin _xmetabolism |
| 650 | 0 | 4 |
_aDisease _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aGenetic Variation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydralazine _xmetabolism |
| 650 | 0 | 4 |
_aIsoniazid _xmetabolism |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 |
_aPharmaceutical Preparations _xmetabolism |
| 650 | 0 | 4 |
_aPhenelzine _xmetabolism |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aProcainamide _xmetabolism |
| 650 | 0 | 4 | _aRacial Groups |
| 650 | 0 | 4 |
_aSparteine _xmetabolism |
| 650 | 0 | 4 |
_aSulfasalazine _xmetabolism |
| 773 | 0 |
_tDrugs _gvol. 29 _gno. 4 _gp. 342-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00003495-198529040-00003 _zAvailable from publisher's website |
| 999 |
_c2865827 _d2865827 |
||